308 related articles for article (PubMed ID: 19340428)
1. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H
Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428
[TBL] [Abstract][Full Text] [Related]
2. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.
van't Veer MB; Brooijmans AM; Langerak AW; Verhaaf B; Goudswaard CS; Graveland WJ; van Lom K; Valk PJ
Haematologica; 2006 Jan; 91(1):56-63. PubMed ID: 16434371
[TBL] [Abstract][Full Text] [Related]
4. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
5. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity.
Mansouri M; Sevov M; Fahlgren E; Tobin G; Jondal M; Osorio L; Roos G; Olivecrona G; Rosenquist R
Leuk Res; 2010 Mar; 34(3):301-6. PubMed ID: 19709746
[TBL] [Abstract][Full Text] [Related]
7. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
10. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
Laurenti L; De Padua L; Tarnani M; Piccirillo N; Falcucci P; D'Arena G; Innocenti I; Marietti S; Efremov DG; Chiusolo P; Zini G; Sora' F; Sica S; Leone G
Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
[TBL] [Abstract][Full Text] [Related]
11. Significance of VH genes mutation status for prognosis of CLL patients.
Bilous N; Abramenko I; Kryachok I; Bazyka D; Chumak A; Bebeshko V
Exp Oncol; 2005 Dec; 27(4):325-9. PubMed ID: 16404355
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
Cancer Sci; 2009 Dec; 100(12):2346-53. PubMed ID: 19824994
[TBL] [Abstract][Full Text] [Related]
13. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
14. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.
Bomben R; Dal-Bo M; Benedetti D; Capello D; Forconi F; Marconi D; Bertoni F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Luciano F; Sozzi E; Cattarossi I; Zucchetto A; Rossi FM; Bulian P; Zucca E; Nicoloso MS; Degan M; Marasca R; Efremov DG; Del Poeta G; Gaidano G; Gattei V
Clin Cancer Res; 2010 Jan; 16(2):620-8. PubMed ID: 20068100
[TBL] [Abstract][Full Text] [Related]
15. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia.
Vasconcelos Y; Davi F; Levy V; Oppezzo P; Magnac C; Michel A; Yamamoto M; Pritsch O; Merle-Béral H; Maloum K; Ajchenbaum-Cymbalista F; Dighiero G
J Clin Oncol; 2003 Nov; 21(21):3928-32. PubMed ID: 14581416
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
Bomben R; Dal Bo M; Capello D; Forconi F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Zucchetto A; Bertoni F; Rossi FM; Bulian P; Cattarossi I; Ilariucci F; Sozzi E; Spina V; Zucca E; Degan M; Lauria F; Del Poeta G; Efremov DG; Marasca R; Gaidano G; Gattei V
Br J Haematol; 2009 Feb; 144(4):492-506. PubMed ID: 19036101
[TBL] [Abstract][Full Text] [Related]
17. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.
Tobin G; Thunberg U; Laurell A; Karlsson K; Aleskog A; Willander K; Söderberg O; Merup M; Vilpo J; Hultdin M; Sundström C; Roos G; Rosenquist R
Haematologica; 2005 Apr; 90(4):465-9. PubMed ID: 15820941
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
20. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
